Penny Stocks Alert Watch: TPIM
|
||||||||||
|
||||||||||
|
|
||||||||
|
Business Summary: TPIM
TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or ‘accelerant’ to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens among others. Article: More on TPIM Make sure you add TPIM to your watch list, one of my alerts last week did roughly 400% in just a few days so it's possible these things can move fast!!! TPIM knows that cancer is one of the top killing diseases out there. The National Cancer Institute expects cancer to be the leading cause of death in the USA within 5 years. TPIM is marketing towards a sector that is costing billions of dollars. According to the National Institutes of Health, the annual costs of cancer in 2007 were estimated to be $219.2 billion! According to the American Cancer Society (ACS), there were 5.4 million cancer cases and 2.9 million cancer deaths that were reported in developed nations last year! TPIM's technology has broad applications in developing therapeutic and preventative vaccines. The vaccine market is estimated to reach $21 billion by 2010!! Traditional approaches to cancer treatments have included surgery, radiation therapy and chemotherapy. Because of the difficulty in removing or destroying all cancer cells, these approaches leave a high mortality rate and numerous side effects for many patients. TPIM's alternative to the traditional approaches to cancer treatment is based on increased knowledge of the human genome and immune system. TPIM's vaccine technology is based on modulating the activity of the antigen processing machinery (APM) to increase effective presentation of antigens to the immune system. Transporters associated with antigen processing (TAP) play a major role in the antigen processing pathway by supplying suitable antigenic peptides to the MHC class I complex. Nearly all cell types display MHC class I antigen on their surface and provide the information to the immune system. The immune system uses this information to selectively destroy cancerous cells or those infected with pathogens. When a virus infects a cell, the viral protein components are degraded by the proteasome into smaller peptide components; TAP then facilitates the binding of the foreign peptides of viral origin to the MHC class I complex and these are subsequently display on the infected cell’s surface. Cytotoxic T-Cells recognize foreign peptides bound to the MHC class I antigen on the cell surface and destroy infected cells to prevent the spread of this infection. To see how TPIM's TAP works, check out: http://www.tapimmune.com/technology/tech_platform/ Although protective vaccines against various infectious diseases, such as AIDS and smallpox, are a societal priority, they remain a scientific challenge to develop and optimize. TPIM knows that the threat of bioterrorism has increased the need and urgency for new and effective vaccines. Unfortunately the penalty of implementing new vaccines includes the toxic side effects to which the vaccine candidate is exposed. A significant number of individuals inoculated with a new vaccine against smallpox, for example, may suffer toxicity due to vaccination. Another challenge to overcome in the production of vaccines is the creation of sufficient doses to vaccinate a large population. TPIM's vaccine platform demonstrates that even low, suboptimal doses of vaccines, confers protective immunity against lethal viral loads during viral challenges. This is a new paradigm in the treatment of infectious disease and could significantly advance the development of new vaccines as well as improve those that already exist. According to estimates at one point by World Information Technologies Inc., the bioterrorism market will reach $10 billion this year! TPIM's technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens among others. TPIM's strategy for growth is to conduct preclinical vaccine programs and move successes through to human trials, discover, acquire and develop technologies that modulate antigen presentation, commercialize proprietary products through corporate alliances, and develop business partnerships that enhance the efficacy of other immunotherapeutic and vaccine products. Make sure you always do your own research. More information on TPIM is available at their website: http://www.tapimmune.com |
|
| Copyright 2008 www.level2stockquotes.com |
| Copyright and Disclaimer - Privacy Policy - Contact-Us - Popular-Links |